Mechanistically, ANXA6 engages in interactions with EGFR and impedes the ubiquitin-proteasome pathway, thereby facilitating the accumulation of active EGFR and fostering tumor proliferation and dissemination (Li et al., 2021). Here, EGFR is linked to neoplasm.